STOCKHOLM — People with difficult to diagnose kidney disease s linked to nephrotic syndrome show uniquely high levels of antinephrin autoantibodies, suggesting a novel biomarker and breakthrough development in diagnosing and managing the diseases.
For the trial, they enrolled 357 patients in the United States and Europe with MCD and FSGS, as well as other glomerular diseases, including -naive patients with active MCD and idiopathic nephrotic syndrome, the prevalence of antinephrin autoantibodies was as high as 69% and 90%, respectively. To further investigate the potential effects of nephrin immunization, the authors conducted studies on mice models that mimicked MCD, and importantly, they found that single nephrin immunization led toAlthough previous studies have suggested the presence of antinephrin autoantibodies,"the difficulty has been in the detection," co-author Tobias B. Huber, MD, also of the University Medical Center Hamburg-Eppendorf, explained while presenting the study.
"Such antibody quantification can potentially transform the management of nephrotic syndromes by providing noninvasive alternatives for diagnosis, enhancing treatment evaluation, and improving kidney-transplantation strategies in patients with recurrent primary FSGS," the authors explain. , Ivan Rychlik, MD, PhD, Department of Medicine, Charles University, Prague, Czech Republic, said the study has important implications.
Source: Healthcare Press (healthcarepress.net)
Chronic Kidney Failure CKD - Chronic Kidney Disease Chronic Kidney Disease CKD Renal Failure Renal Insufficiency Kidney Insufficiency Kidney Failure Renal Impairment Renal Disease Kidney Disease Kidney Disorder Renal Disorder Nephropathy End Stage Renal Disease ESRD - End Stage Renal Disease ESRD ESKD End-Stage Kidney Disease (ESKD)
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: ScienceDaily - 🏆 452. / 53 Read more »
Source: SciTechDaily1 - 🏆 84. / 68 Read more »
Source: ScienceDaily - 🏆 452. / 53 Read more »
Source: Medscape - 🏆 386. / 55 Read more »
Source: HHSGov - 🏆 147. / 63 Read more »
Source: Medscape - 🏆 386. / 55 Read more »